Coronavirus vaccine - Emergex
Alternative Names: COVID-2019 vaccine - EmergexLatest Information Update: 09 Oct 2023
At a glance
- Originator Emergex Vaccines
- Class COVID-19 vaccines
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 05 Oct 2023 Emergex enters into collaboration agreement with Vaccine Industrial Company advancing Emergex’s novel T cell-priming immune candidates against infectious diseases
- 01 Jul 2022 Emergex Vaccines signs heads of terms for a collaboration with Molecular Biology Institute of Paraná (IBMP) for vaccine candidates in Brazil
- 05 Jan 2021 Emergex Vaccines and Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz) agree to co-develop coronavirus vaccine in Brazil for COVID-2019 infections (Prevention)